Cephalon warns docs of Fentora death link

Share this article:

Drug maker Cephalon this week issued a warning to doctors about deaths linked to its powerful painkiller Fentora, the FDA said.

Cephalon spokeswoman Candace Steele told Reuters news service that three deaths occurred during a fairly short period of time this summer and that they were most likely caused by respiratory failure.

The deaths were reported to have occurred in cases where Fentora was given to patients unable to tolerate opioid therapy, or in patients getting the drug inappropriately as a substitution for another drug, such as Fentora predecessor Actiq.

Fentora and Actiq, are approved by the FDA only for use in cancer patients, but are known to be prescribed by doctors as an “off-label” treatment for conditions such as headaches and back pain.

Cephalon's marketing practices involving the two drugs are currently under investigation in three separate probes – investigations by the US attorney in Philadelphia and Connecticut attorney general and a congressional probe into off-label treatments.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.